Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 4/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3880948 | 0.90 | DPP4 (0.45) | DPP4IRAK4DPP9FAPKCNH2 | |
| Trifluoroacetic Acid SCHEMBL3885741 | 0.89 | DPP4 (0.53) | DPP4DPP9FAPP2RX3 | |
| Trifluoroacetic Acid SCHEMBL3881058 | 0.88 | DPP4 (0.43) | DPP4DPP9FAPP2RX3L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL3877001 | 0.88 | DPP4 (0.49) | DPP4IRAK4DPP9FAPKCNH2 | |
| Trifluoroacetic Acid SCHEMBL3883168 | 0.85 | DPP4 (0.41) | DPP4DPP9FAPKCNH2P2RX3 | |
| SCHEMBL3881063 | 0.85 | DPP4 (0.42) | DPP4DPP9FAPP2RX3L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL3887064 | 0.85 | DPP4 (0.50) | DPP4DPP9FAPP2RX3 | |
| Trifluoroacetic Acid SCHEMBL3885657 | 0.83 | DPP4 (0.46) | DPP4DPP9FAPKCNH2P2RX3 | |
| Trifluoroacetic Acid SCHEMBL3879206 | 0.83 | DPP4 (0.41) | DPP4DPP9FAPKCNH2P2RX3 | |
| Trifluoroacetic Acid SCHEMBL5718906 | 0.83 | DPP4 (0.60) | DPP4DPP9FAPL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524847-B2 | Fused 1,3-dihydro-imidazole ring compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| US-20060111362-A1 | 1,3-Dihydroimidazole ring compound | EISAI CO., LTD. (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1568699-A1 | 1,3-DIHYDROIMIDAZOLE FUSED-RING COMPOUND | Eisai Co., Ltd. (JP) | 2005-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111362-A1 | 1,3-Dihydroimidazole ring compound | NR2C2, NR0B2, DPP4 | DPP4 3/4885IRAK4 2148/4885DPP9 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.